{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:37:26Z","timestamp":1790548646922,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1038\/nrclinonc.2009.185","type":"journal-article","created":{"date-parts":[[2009,12,23]],"date-time":"2009-12-23T07:54:06Z","timestamp":1261554846000},"page":"55-58","source":"Crossref","is-referenced-by-count":12,"title":["Interaction between capecitabine and brivudin in a patient with breast cancer"],"prefix":"10.1038","volume":"7","author":[{"given":"Jos\u00e9 M.","family":"Baena-Ca\u00f1ada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obdulia","family":"Garc\u00eda-Olmedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Jim\u00e9nez-B\u00e1rcenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Muriel-Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrclinonc2009185_CR1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1248\/yakushi1947.117.10-11_910","volume":"117","author":"T Watabe","year":"1997","unstructured":"Watabe, T., Okuda, H. & Ogura, K. Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil [Japanese]. Yakugaku Zasshi 117, 910\u2013921 (1997).","journal-title":"Yakugaku Zasshi"},{"key":"BFnrclinonc2009185_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2125.1998.00050.x","volume":"46","author":"RB Diasio","year":"1998","unstructured":"Diasio, R. B. Sorivudine and 5-fluorouracil: a clinically significant drug\u2013drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br. J. Clin. Pharmacol. 46, 1\u20134 (1998).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrclinonc2009185_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00008571-199702000-00005","volume":"7","author":"H Nakayama","year":"1997","unstructured":"Nakayama, H. et al. Intestinal anaerobic bacteria hydrolyze sorivudine, producing the high blood concentration of 5-(E)-5-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 7, 5\u201343 (1997).","journal-title":"Pharmacogenetics"},{"key":"BFnrclinonc2009185_CR4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0026-895X(24)26498-1","volume":"57","author":"T Nishiyama","year":"2000","unstructured":"Nishiyama, T. et al. Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracyl in the presence of NADPH. Mol. Pharmacol. 57, 899\u2013905 (2000).","journal-title":"Mol. Pharmacol."},{"key":"BFnrclinonc2009185_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0166-3542(03)00065-2","volume":"59","author":"SW Wassilew","year":"2003","unstructured":"Wassilew, S. W., Wutzler, P. & Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res. 59, 49\u201356 (2003).","journal-title":"Antiviral Res."},{"key":"BFnrclinonc2009185_CR6","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","volume":"68","author":"E De Clercq","year":"2004","unstructured":"De Clercq, E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem. Pharmacol. 68, 2301\u20132315 (2004).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrclinonc2009185_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2310\/7750.2008.07028","volume":"12","author":"M Hogeling","year":"2008","unstructured":"Hogeling, M., Howard, J., Kanigsberg, N. & Finkelstein H. Onycholysis associated with capecitabine in patients with breast cancer. J. Cutan. Med. Surg. 12, 93\u201395 (2008).","journal-title":"J. Cutan. Med. Surg."},{"key":"BFnrclinonc2009185_CR8","first-page":"1","volume":"22","author":"AE R\u00e4tz Bravo","year":"2009","unstructured":"R\u00e4tz Bravo, A. E., Hofer, S., Kr\u00e4henb\u00fchl, S. & Ludwig C. Fatal drug\u2013drug interaction of brivudine and capecitabine. Acta Oncol. 22, 1\u20133 (2009).","journal-title":"Acta Oncol."},{"key":"BFnrclinonc2009185_CR9","first-page":"626","volume":"148","author":"EA Hooiveld","year":"2004","unstructured":"Hooiveld, E. A., van Kuilenburg, A. B., Haanen, J. B. & Westermann A. M. Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency [Dutch]. Ned. Tijdschr. Geneeskd. 148, 626\u2013628 (2004).","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"BFnrclinonc2009185_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/00008571-199812000-00001","volume":"8","author":"HL McLeod","year":"1998","unstructured":"McLeod, H. L. et al. Nomenclature for human DPYD alleles. Pharmacogenetics 8, 455\u2013459 (1998).","journal-title":"Pharmacogenetics"},{"key":"BFnrclinonc2009185_CR11","volume-title":"To Err Is Human: Building a Safer Health System","author":"LT Kohn","year":"1999","unstructured":"Kohn, L. T. et al. (Eds) To Err Is Human: Building a Safer Health System (National Academies Press, Washington DC, 1999)."},{"key":"BFnrclinonc2009185_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s12094-006-0138-1","volume":"8","author":"MJ Huertas","year":"2006","unstructured":"Huertas, M. J., Baena-Ca\u00f1ada, J. M., Mart\u00ednez, M. J., Arriola, E. & Garc\u00eda, M. V. The impact of computerised chemotherapy prescriptions on the prevention of medication errors. Clin. Transl. Oncol. 8, 821\u2013825 (2006).","journal-title":"Clin. Transl. Oncol."},{"key":"BFnrclinonc2009185_CR13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1001\/archinte.1995.00430180043006","volume":"155","author":"JA Johnson","year":"1995","unstructured":"Johnson, J. A. & Bootman, J. L. Drug-related morbidity and mortality: a cost-of-illness model. Arch. Intern. Med. 155, 1949\u20131956 (1995).","journal-title":"Arch. Intern. Med."},{"key":"BFnrclinonc2009185_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.1974.03230310023021","volume":"228","author":"GJ Caranasos","year":"1974","unstructured":"Caranasos, G. J., Stewart, R. B. & Cluff, L. E. Drug-induced illness leading to hospitalization. JAMA 228, 713\u2013717 (1974).","journal-title":"JAMA"},{"key":"BFnrclinonc2009185_CR15","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1001\/jama.296.15.1858","volume":"296","author":"DS Budnitz","year":"2006","unstructured":"Budnitz, D. S. et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296, 1858\u20131866 (2006).","journal-title":"JAMA"},{"key":"BFnrclinonc2009185_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1345\/aph.1A333","volume":"36","author":"PJ McDonnell","year":"2002","unstructured":"McDonnell, P. J. & Jacobs, M. R. Hospital admissions resulting from preventable adverse drug reactions. Ann. Pharmacother. 36, 1331\u20131336 (2002).","journal-title":"Ann. Pharmacother."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.185","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T21:25:37Z","timestamp":1739654737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["BFnrclinonc2009185"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2009.185","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}